ACP
NGNE icon

Acuta Capital Partners’s Neurogene NGNE Stock Holding History

Acuta Capital Partners’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-18,625
Closed -$4.59M – 38
2019
Q4 		$4.59M Buy
+18,625
New +$1.86M 1.14% 22

Other funds holding NGNE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Acuta Capital Partners's NGNE Position: Q1 2020 in Review

Acuta Capital Partners sold out of Neurogene (NGNE) in Q1 2020, closing a stake of 18,625 shares — an estimated $4.59M sold.

Acuta Capital Partners first reported a position in NGNE in Q4 2019 and held it in 1 quarter. The position peaked at $4.59M in Q4 2019. 60 funds tracked by Wall St. Rank hold NGNE as of Q1 2020.

  • Acuta Capital Partners reported no remaining Neurogene position as of Q1 2020 after selling out during the quarter.
  • Acuta Capital Partners sold 18,625 Neurogene shares in Q1 2020, an estimated $4.59M.
  • Acuta Capital Partners first reported a position in Neurogene in Q4 2019 and held it in 1 quarter.
  • Acuta Capital Partners's Neurogene position peaked at $4.59M in Q4 2019.
  • 60 funds tracked by Wall St. Rank held Neurogene as of Q1 2020.

Based on Acuta Capital Partners's 13F filing for Q1 2020, filed 15 May 2020.